DAIEN, V.; FINGER, R. P.; TALKS, J. S.; MITCHELL, P.; WONG, T. Y.; SAKAMOTO, T.; ELDEM, B. M.; KOROBELNIK, Jean-Francois

doi:10.1136/bjophthalmol-2020-317434

Langue

Article de revue

Ce document a été publié dans

The British Journal of Ophthalmology. 2021-10-21, vol. 105, n° 11

Résumé en anglais

The aim of this work was to evaluate the contribution of real-world evidence (RWE) in changing anti-vascular endothelial growth factor (VEGF) therapy treatment practices and improving real-world treatment strategies for neovascular age-related macular degeneration (nAMD).A PubMed literature search was performed to review the large number of English-language studies conducted to investigate the real-world effectiveness of anti-VEGF (aflibercept and ranibizumab) treatment paradigms available for nAMD.The evidence for pro re nata (PRN), treat-and-extend (T&E) and fixed bimonthly dosing regimens for anti-VEGF treatment of nAMD were reviewed and findings are summarised. RWE demonstrated that T&E regimens optimise visual outcomes while reducing burden on patients, clinics and physicians, compared with both fixed-dose and PRN regimens.RWE has helped to develop and improve real-world treatment strategies in nAMD, with the aim of optimising visual outcomes and reducing treatment burden in clinical practice. Of the various regimens, a T&E regimen is most likely to adequately balance clinical outcomes and treatment burden for patients with nAMD.< Réduire

URI

https://oskar-bordeaux.fr/handle/20.500.12278/26752

DOI

http://dx.doi.org/10.1136/bjophthalmol-2020-317434

Unités de recherche

Bordeaux Population Health Research Center (BPH) - UMR 1219

Voir/Ouvrir

Métadonnées

Partager cette publication !

Licence d’utilisation du document

Evolution of treatment paradigms in neovascular age-related macular degeneration: a review of real-world evidence

Langue

Ce document a été publié dans

Résumé en anglais

URI

DOI

Unités de recherche